



COMPANY RELEASE

29 May 2007

Theodor Dingermann, Ph.D. joins AION Scientific Advisory Board

Perth, Australia – AION Diagnostics Inc, a nano-diagnostics company commercializing medical imaging agents, today announced the appointment of Theodor Dingermann, Ph.D. to its Scientific Advisory Board.

Professor Dingermann has over 30 years experience in the German pharmaceutical industry. He is the biotechnology advisor to the State of Hesse as well as Editor-in-chief of two leading German pharmaceutical journals; "DIE PHARMAZIE" and "Pharmazie in unserer Zeit."

"We very much look forward to the expertise in molecular biology and biochemistry Prof. Dingermann will bring to AION, particularly to our Molecular Imaging platform," said AION President and CEO, Dr. Anna Kluczevska.

Since 1990, Prof. Dingermann has been Full Professor of Pharmaceutical Biology at Goethe University in Frankfurt, Germany. He is Chairman of the working group of biopharmaceuticals and Vice-Chairman on pharmaceutical biology of the German Pharmacopeia Commission. From 2000 to 2004 he was President of the German Pharmaceutical Society. Prof. Dingermann studied Pharmacy at the University of Erlangen, Germany. On obtaining his Ph.D. in Biochemistry, he worked as a Post-Doctoral Research Fellow at Yale University, New Haven.

The AION Scientific Advisory Board is chartered to contribute independent scientific and strategic advice to the Company's operations.

- ENDS -

Released by:

AION Diagnostics

Alexandra Brown

Ph: +61 (8) 6461 9400

alexandra_brown@aiondiagnostics.com

European Public Relations

Dr. Eva Reuter

Ph: +49 (254) 393 0740

e.reuter@e-reuter-ir.com

NOTES TO EDITORS:

AION Diagnostics (AION) is a global biotechnology company dedicated to the commercialization of medical imaging contrast and molecular imaging agents for early stage detection of critical diseases. Founded in 2004, AION secured strategic alliances with universities, research institutions and industry partners internationally.

Exploiting the 10-year history of discoveries of porous silicon made at the former UK Defence Evaluation Agency (now QinetiQ) and backed by USD\$50 million in cumulative previous investment in the technology, AION have developed modified porous silicon (mpSi) which has been proven visible across all major imaging modalities. AION is leveraging the unique visualization capabilities of the mpSi technology platform with its biodegradable and biocompatible properties to produce imaging product divisions in Marking, Contrast and Molecular Imaging Agents. Additionally, one such strategic objective is the development of collaborations incorporating the mpSi platform with other materials to create superior versions of existing products.

Continuing to strive for better solutions to unmet diagnostic needs, AION's products are committed to the timely visualization of pathologies in a manner which may facilitate prevention rather than treatment of disease.

This press release and the information contained therein do not constitute an offer for sale or a solicitation for submission of an offer for purchase or subscription of shares in AION Diagnostics Inc in Germany nor outside Germany, especially in the United States, Canada, Japan or the United Kingdom and Northern Ireland. This press release is provided solely for information purposes.